ClinicalTrials.gg
RecruitingNCT06384716Updated Apr 25, 2024

Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program Patients With Multiple Sclerosis

An interventional study of rehabilitation programme based on motor control of core muscles in Multiple Sclerosis, Pelvic Floor Disorders and Incontinence, Urinary, sponsored by Universidad Europea de Madrid. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-04-25.

Sponsored by Universidad Europea de Madrid · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 230 studies in Multiple Sclerosis with a site in Spain — 35 open to participants now, 56 under way, 14 of them phase 3. Multiple Sclerosis · Spain.

Planned enrollment
155th of 202
32 · median 137
Started
2024
with 17 others
No phase
68 of 230
22 open now
Primary completion
2024-07
later than 3 of 55 live
Registered
181st of 230
by date

Among the 230 studies in Multiple Sclerosis with a site in Spain, this one is the 155th largest by planned enrollment of the 202 interventional ones that give a count, is one of 18 that started in 2024, is one of 68 with no phase, reaches primary completion later than 3 of the 55 other live ones, and was the 181st registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

35 of the 230 studies in Multiple Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies in Multiple Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

Given the structural relationship of the CORE as a whole, in this study we propose an intervention based on the global motor control of all the structures that make up the CORE to assess its effectiveness on urinary incontinence, sexual dysfunction and balance, as well as its relationship with respiratory function. According to our hypothesis, a global intervention could also be taken into account during conventional treatment in the future, helping to prevent genitourinary dysfunctions derived from alterations in motor control.

Read the detailed description

Main objective:

To establish the effect of core motor control training on pelvic floor functionality in patients with multiple sclerosis.

Specific objective: To assess the effect of core motor control training on urinary incontinence.

  • To assess the effect of core motor control training on urinary incontinence in patients with multiple sclerosis.
  • To assess the effect of core motor control training on quality of life in patients with multiple sclerosis.
  • To assess the effect of core motor control training on sexual dysfunction in patients with multiple sclerosis.
  • To assess the effect of core motor control training on balance in patients with multiple sclerosis.
  • To test the relationship between respiratory functionality and pelvic floor dysfunctions in patients with multiple sclerosis.
03

Conditions studied

  • Multiple Sclerosis
  • Pelvic Floor Disorders
  • Incontinence, Urinary
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age between 18 and 70 years.
  • Confirmed diagnosis of Multiple Sclerosis based on McDonald criteria, with an evolution time of more than two years (remitting or progressive) (24).
  • Multiple Sclerosis Disability Status Scale (EDSS) score between 2 (minimal disability in one of the functional systems), and 7.5 (inability to take more than a few steps. Limited to wheelchair and transfer support. Ability to move the chair, but not all day if the chair is conventional and lacks a motor) (25, 26).
  • Stable medical treatment for at least six months prior to surgery (26).
  • Absence of cognitive impairment, with ability to understand instructions and score 24 or higher on the Minimental Test (27).
  • Urinary incontinence as a consequence of neurological involvement.

Exclusion criteria

Exclusion Criteria:

    • Diagnosis of another neurological disease or musculoskeletal disorder other than MS.
  • Diagnosis of any cardiovascular, respiratory, genitourinary, metabolic or other conditions that may interfere with this study.
  • Having presented urinary incontinence prior to the diagnosis of MS.
  • Have suffered an exacerbation or hospitalisation in the last 3 months before starting the assessment protocol, or during the therapeutic intervention process.
  • Have received a course of intravenous or oral 6 months prior to the start of the assessment protocol and within the intervention period of the study duration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Experimental Group 1

    The intervention group will come to receive the treatment focused on training the motor control of the CORE. This intervention will consist of two sessions per week in which different levels of intervention will be established: 1. - First week: Sensitisation and voluntary work of the pelvic floor musculature without increasing the increase in intra-abdominal pressure. 2. - Second week: Work on respiratory motor control and activation of the pelvic floor. 3. - Third and fourth week: Motor control work with progressive increase in intra-abdominal pressure. 4. - Fifth and sixth week: Work on dynamic motor control in dual-task situations. 5. - Seventh and eighth week: Core motor control work in functional activities.

    Other: rehabilitation programme based on motor control of core muscles

  • No intervention
    Control group

    The control group will be evaluated before and after 8 weeks and will continue with their usual treatment.

Interventions

  • Otherrehabilitation programme based on motor control of core muscles

    The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.

06

What researchers measure

Primary outcomes

  1. Difference in the percentage of initial and final maximum activity of the pelvic floor muscles.

    EMG

    Time frame: 8 weeks

  2. - Differences between the initial and final thickness of the oblique abdominis and transverse oblique muscles by ultrasound.

    US

    Time frame: 8 weeks

  3. - Differences in the assessment of health-related quality of life before and after the intervention measured with the I-QOL questionnaire.

    IQOL

    Time frame: 8 weeks

  4. - Differences in the assessment of female UI before and after intervention using the I-CIQ questionnaire

    I-CIQ

    Time frame: 8 weeks

Secondary outcomes

  1. - Difference in the percentage of initial and final maximum activity of the paravertebral musculature activity.

    EMG

    Time frame: 8 weeks

  2. - Differences between initial and final amplitude of initial and final diaphragmatic excursion by ultrasound.

    US

    Time frame: 8 weeks

  3. - Difference between initial and final FVC/- Differences between the initial and final peak expired volume (FEV1)

    spirometry

    Time frame: 8 weeks

  4. differences between peak expiratory pressure (PEM) and minimum initial and end inspiratory pressure (MIP).

    PIM/PEM

    Time frame: 8 weeks

  5. balance

    trunk control test and Berg Balance test

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jul 2024, 4 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 25, 2024
StartActual
Feb 19, 2024
Primary completionEst.
Jul 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Apr 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06384716
Lead sponsor
Universidad Europea de Madrid
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Feb 19, 2024
Primary completion
Jul 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Apr 25, 2024

Study contacts

Cecilia Estrada-Barranco, PhD
Contact
cecilia.estrada@universidadeuropea.es
686166483
Estherl Delgado, PhD
Contact
esther.delgado@universidadeuropea.es
686166483
Cecilia Estrada-Barranco, PhD
principal investigator · Universidad Europea de Madrid

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion